Genentech And Array Join ChK-1 Programs | Chemical & Engineering News
Volume 89 Issue 33 | p. 17 | Concentrates
Issue Date: August 15, 2011

Genentech And Array Join ChK-1 Programs

Department: Business
News Channels: Biological SCENE
Keywords: ChK-1, drug discovery

Genentech will pay Array BioPharma $28 million as part of a deal to jointly develop the companies’ small-molecule inhibitors of Checkpoint kinase 1 (ChK-1), a protein implicated in cancer cell survival. Included in the pact are Genentech’s GDC-0425, in Phase I studies, and Array’s ARRY-575, which has yet to be tested in humans. Array could gain up to $685 million in milestone payments along with royalties on any drug that is commercialized under the pact from either firm. ChK-1 helps a tumor cell to repair damaged DNA after exposure to chemotherapy; if the protein is blocked, chemotherapy should kill cancer cells more effectively.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment